Methotrexat Sandoz

Methotrexate, the active ingredient in Methotrexat Sandoz, is an antimetabolite presented as an injection for intramuscular, intravenous, or subcutaneous use. It treats rheumatoid arthritis, psoriasis, acute lymphoblastic leukemia, osteosarcoma, and gestational trophoblastic disease in the appropriate patient populations.

GNH USA supplies Methotrexat Sandoz as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, and pharmacies worldwide. The product complies with European Union regulatory standards and is manufactured under GMP conditions.

Methotrexate is employed in autoimmune and oncologic conditions where folate pathway inhibition provides therapeutic benefit.

- Rheumatoid arthritis: reduces joint inflammation and slows disease progression. - Psoriasis: improves skin lesions and decreases plaque formation. - Acute lymphoblastic leukemia: induces remission by inhibiting malignant cell proliferation. - Osteosarcoma: contributes to tumor control as part of multi‑agent chemotherapy. - Gestational trophoblastic disease: facilitates resolution of trophoblastic tissue.

Methotrexate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea and vomiting - Fatigue - Elevated liver enzymes

Serious or Rare Side Effects: - Bone marrow suppression leading to pancytopenia - Pulmonary toxicity (interstitial pneumonitis) - Life‑threatening skin reactions such as Stevens‑Johnson syndrome

When using methotrexate, careful monitoring and specific precautions are required to minimize risks.

- Liver function: monitor transaminases regularly to detect hepatotoxicity. - Renal function: assess creatinine clearance before each dose and adjust as needed. - Pregnancy: contraindicated (Category X); ensure effective contraception for both sexes. - Infection risk: screen for active infections and avoid live vaccines during therapy. - Hematology: perform complete blood counts to identify bone marrow suppression early. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Methotrexate interacts with several medicines; some combinations should be avoided while others require close monitoring.

Major Interactions (Avoid): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): increase methotrexate toxicity. - Trimethoprim‑sulfamethoxazole: enhances myelosuppression. - Live vaccines: risk of severe infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Penicillins (e.g., ampicillin): may reduce methotrexate clearance. - Warfarin: may potentiate anticoagulant effect, requiring INR monitoring.